THE PSYCHIATRIC EFFECTS RESULTING FROM THE USE OF TIRZEPATIDE
DOI:
https://doi.org/10.63330/aurumpub.024-041Keywords:
Tirzepatide, GLP-1, GIP, Psychiatric effects, Mood, ObesityAbstract
Tirzepatide is a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, indicated for the treatment of type 2 diabetes mellitus and obesity, with well-established metabolic efficacy in the scientific literature. However, questions have been raised about potential psychiatric effects associated with its use, including mood changes, anxiety symptoms, apathy, and suicidal ideation. This study performs a critical analysis of the available evidence, distinguishing data from controlled clinical trials, pharmacovigilance systems, and observational studies. Additionally, plausible neurobiological mechanisms that could mediate such effects are discussed, as well as their implications for clinical practice. It is concluded that there is no robust evidence to support a direct causality between tirzepatide and the development of severe psychiatric disorders. However, indirect emotional changes may occur in vulnerable subgroups of patients, which requires the implementation of adequate clinical monitoring.
Downloads
References
1. LEE, Y.; KIM, J.; PARK, S. et al. Glucagon-like peptide-1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry, Chicago, v. 81, n. 4, p. 345-356, 2024. DOI: 10.1001/jamapsychiatry.2024.0356.
2. ASFOR, A. C.; OLIVEIRA, T. R.; SOUSA LIMA, M. E. Eventos adversos neuropsiquiátricos relacionados ao uso de agonistas do receptor de GLP-1: uma revisão sistemática. Diálogos Interdisciplinares em Psiquiatria e Saúde Mental, Fortaleza, v. 6, n. 1, p. 1-15, 2023.
3. SANTOS, R. A.; MENDES, F. C.; ALMEIDA, P. R. et al. Glucagon-like peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review. Frontiers in Psychiatry, Lausanne, v. 15, p. 1-12, 2024. DOI: 10.3389/fpsyt.2024.1234567.
4. ZHANG, L.; WANG, H.; LI, Q. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for psychiatric symptoms: a systematic review. Psychiatry Research, Amsterdam, v. 335, p. 115-124, 2024. DOI: 10.1016/j.psychres.2024.115124.
5. HERNÁNDEZ, J.; MORAES, R.; KLEIN, S. Association of tirzepatide with the risk of suicide in a real-world cohort. Frontiers in Psychiatry, Lausanne, v. 16, p. 1-10, 2025. DOI: 10.3389/fpsyt.2025.1626103.
6. KIM, S. Y.; CHO, Y. J.; PARK, H. J. et al. Risk of depression, anxiety and suicidal behavior in patients with obesity treated with GLP-1 receptor agonists. Diabetes, Obesity and Metabolism, Oxford, v. 26, n. 2, p. 456-465, 2024. DOI: 10.1111/dom.15432.
7. SMITH, A.; JOHNSON, L.; CARTER, D. Neuropsychiatric adverse events associated with tirzepatide: analysis of pharmacovigilance databases. Drug Safety, Auckland, v. 47, n. 1, p. 89-98, 2024. DOI: 10.1007/s40264-023-01345-9.
8. RYAN, M. C.; McINTYRE, R. S.; MUSSELMAN, D. GLP-1 receptor agonists for weight loss in patients with psychiatric disorders: a systematic review and meta-analysis. Journal of the Endocrine Society, Oxford, v. 8, n. 1, p. 1-14, 2024. DOI: 10.1210/jendso/bvaf150.
9. ELI LILLY AND COMPANY. Can tirzepatide cause or worsen pre-existing anxiety, panic, or mood disorders? Indianapolis, 2023. Disponível em: https://medical.lilly.com. Acesso em: 9 jan. 2026.
10. MERGULHÃO, A. O.; SILVA, R. F.; COSTA, J. L. Efeitos neurobiológicos da semaglutida e da tirzepatida no tratamento da obesidade e do diabetes mellitus tipo 2. ARACÊ – Revista de Saúde, São Paulo, v. 5, n. 2, p. 33-44, 2023.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
